# Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.

> **NCT01129713** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Effexus Pharmaceutical** · enrollment: 40 (estimated)

## Conditions studied

- Gastroesophageal Reflux Disease (GERD)
- Heartburn
- Indigestion

## Interventions

- **DRUG:** Secretol
- **DRUG:** Nexium

## Key facts

- **NCT ID:** NCT01129713
- **Lead sponsor:** Effexus Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-05
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2014-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01129713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01129713, "Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01129713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*